VoxCell BioInnovation to appear on Bloomberg Television segment

By AI, Created 4:53 PM UTC, May 18, 2026, /AGP/ – VoxCell BioInnovation will be featured May 15 on Inside Business Today on Bloomberg Television in a sponsored segment that spotlights its 3D bioprinted human tissue models for drug development. The company is positioning its vascular-first technology as a way to improve preclinical decisions, reduce late-stage failures and speed better therapies to market.

Why it matters: - VoxCell BioInnovation is targeting one of drug development’s biggest bottlenecks: animal models that do not reliably predict human results. - The company’s human tissue models are designed to give pharmaceutical and biotech teams earlier, more relevant data on drug delivery, efficacy and toxicity. - More predictive preclinical testing could cut costly late-stage failures and shorten timelines for therapies reaching patients.

What happened: - VoxCell BioInnovation will be featured on Inside Business Today, hosted by Bill Rancic and Giuliana Rancic. - The segment airs nationally on Bloomberg Television as sponsored programming on May 15, 2026 at 10:30pm CST/8:30pm PST. - CEO, CSO and co-founder Dr. Karolina Valente and Chief Commercial Officer Graham Craig appear in the interview.

The details: - VoxCell was founded in 2020. - The company builds 3D bioprinted human tissue models for preclinical drug development. - VoxCell’s proprietary technology produces human tissues with micron-scale precision. - The company’s “vascular-first” approach engineers microvascular networks that replicate capillary-level blood vessels. - Those networks are intended to help researchers study how drugs are delivered, how well they work and whether they cause toxic side effects. - VoxCell says more than 90% of drugs that look safe in animal models fail in human clinical trials. - The company says drug development can take more than a decade and cost more than $1 billion per successful drug. - VoxCell says its models fit into existing preclinical workflows and complement current methods rather than replace them. - The company says the approach can support earlier go/no-go decisions for pharmaceutical companies and contract research organizations. - VoxCell says it is working with pharmaceutical companies and CRO partners as demand grows for non-animal testing methods. - The company has a 12,000-square-foot lab and office space. - VoxCell has raised more than $10 million to date.

Between the lines: - The Bloomberg segment gives VoxCell a broader stage as the drug industry faces pressure to find alternatives to animal testing. - The company is aligning its pitch with both scientific and regulatory momentum toward more human-centered research tools. - The emphasis on integration, not replacement, suggests VoxCell is trying to lower adoption barriers for drug developers.

What’s next: - VoxCell is preparing for its next phase of growth as it scales across pharmaceutical and biotech markets. - Viewers can learn more through VoxCell’s website. - More information about the series is available at Inside Business Today.